Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degludec Insulin for Glycemic Control in Critically Ill Patients
NCT06056167Completed
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of insulin degludec in type 2 diabetes mellitus (T2DM) and hyperglycemia, sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoint: The percentage of blood glucose readings at the target glycemic control 140-180 mg/dL at 28 days. Started May 2023; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)hyperglycemia
Beyond the preview
Go deeper on NCT06056167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056167.